Key Points
- Rapidly growing demand for Novo Nordisk’s GLP-1 diabetes and obesity treatments are fattening up its financial results.
- Last month, the company completed a 2-for-1 stock split that put its price under $100.
- Management raised full-year sales growth outlook to 27% to 33%, reflecting the company's massive market share in a pair of fast-growth markets.
- 5 stocks we like better than Novo Nordisk A/S
Upgrade Now
This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.
Already have an account? Log in here.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
